REN and hydrops fetalis: Evidence-based pharmacological therapies, including renin–angiotensin–aldosterone system agents, beta blockers, mineralocorticoid receptor agonists, and ivabradine, are mostly limited to patients with HF with reduced ejection fraction (HFrEF) rather than those with HF with preserved ejection fraction.